Technical Analysis for PSTI - Pluristem Therapeutics, Inc.

Grade Last Price % Change Price Change
F 4.41 1.85% 0.08
PSTI closed up 1.85 percent on Thursday, April 22, 2021, on 44 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Flat
Historical PSTI trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Up 3 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 1.85%
Jack-in-the-Box Bearish Bearish Swing Setup 3.52%
MACD Bullish Signal Line Cross Bullish 3.52%
Lower Bollinger Band Touch Weakness 3.52%
Oversold Stochastic Weakness 3.52%
MACD Bearish Signal Line Cross Bearish 7.56%
New 52 Week Closing Low Bearish 7.56%
Older End-of-Day Signals for PSTI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 5 hours ago
Up 5% about 5 hours ago
Up 3% about 8 hours ago
60 Minute Opening Range Breakout about 8 hours ago
Rose Above 10 DMA about 8 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Pluristem Therapeutics, Inc. Description

Pluristem Therapeutics Inc., a bio-therapeutics company, engages in the research, development, and commercialization of standardized cell therapy products and related technologies for the treatment of life threatening diseases. The company's products are derived from human placenta that is a non-controversial, non-embryonic, and adult cell source. Its Placental adherent stromal cells are grown in the company's proprietary PluriX three-dimensional process that allows cells to grow in a natural environment. The company develops placenta expanded cells (PLX) and peripheral artery disease cells, an allogeneic therapeutic product that is in Phase-II clinical trials for the treatment of intermittent claudication, critical limb ischemia, and Buerger's disease. Its PLX product is developed for the treatment of muscle injury, bone marrow diseases, inflammatory bowel disease, and multiple sclerosis, as well as for pulmonary disorders, acute radiation syndrome, acute myocardial infarction, diabetic diastolic heart failure, neuropathic pain, inflammatory bowel disease, multiple sclerosis, and ischemic stroke for which the product is in various pre-clinical trials. Pluristem Therapeutics Inc. is also involved in the development and commercialization of a PLX cell-based product for the treatment of pulmonary arterial hypertension through its license agreement with the United Therapeutics Corporation. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007. Pluristem Therapeutics Inc. was founded in 2001 and is headquartered in Haifa, Israel.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Diseases Pain Bone Stem Cells Radiation Hypertension Injury Therapeutic Product Heart Failure Multiple Sclerosis Cell Therapy Inflammatory Bowel Disease Stroke Natural Environment Pulmonary Arterial Hypertension Artery Neuropathic Pain Bone Marrow Artery Disease Ischemia Peripheral Artery Disease Infarction Myocardial Infarction Acute Myocardial Infarction Ischemic Stroke United Therapeutics Diastolic Heart Failure Pulmonary Disorders Treatment Of Life Threatening Diseases

Is PSTI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.76
52 Week Low 4.03
Average Volume 479,799
200-Day Moving Average 8.14
50-Day Moving Average 5.50
20-Day Moving Average 4.58
10-Day Moving Average 4.40
Average True Range 0.32
ADX 35.83
+DI 14.94
-DI 26.59
Chandelier Exit (Long, 3 ATRs ) 4.53
Chandelier Exit (Short, 3 ATRs ) 4.98
Upper Bollinger Band 5.08
Lower Bollinger Band 4.08
Percent B (%b) 0.33
BandWidth 21.86
MACD Line -0.32
MACD Signal Line -0.35
MACD Histogram 0.0277
Fundamentals Value
Market Cap 113.04 Million
Num Shares 25.6 Million
EPS -2.86
Price-to-Earnings (P/E) Ratio -1.54
Price-to-Sales 8634.47
Price-to-Book 5.02
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.83
Resistance 3 (R3) 4.83 4.69 4.76
Resistance 2 (R2) 4.69 4.58 4.69 4.74
Resistance 1 (R1) 4.55 4.52 4.62 4.55 4.71
Pivot Point 4.41 4.41 4.45 4.41 4.41
Support 1 (S1) 4.27 4.30 4.34 4.27 4.11
Support 2 (S2) 4.13 4.24 4.13 4.08
Support 3 (S3) 3.99 4.13 4.06
Support 4 (S4) 3.99